Skip to main content
Top

06-05-2024 | Diabetes | Original Article

Global research trends on diabetic islet regeneration (2012–2022): a ten-year bibliometric study

Authors: Yulin Sun, Lingling Jia, Ying Wang, Rong Guo, Tingting Xi, Hua Jiang, Jiachao Xiong

Published in: International Journal of Diabetes in Developing Countries

Login to get access

Abstract

Introduction

Diabetes mellitus (DM), a prevalent chronic metabolic disorder, has seen an escalating incidence each year, thereby imposing significant burdens on both public health and socio-economic structures. Although numerous outstanding studies have focused on the regeneration of diabetic islets, a gap exists in the form of comprehensive bibliometric analyses in this area.

Methods

We employed bibliometric methods to encapsulate and depict the worldwide research directions in this field. Our study engaged in a detailed screening of 552 scholarly articles on diabetic islet regeneration from 2012 to 2022.

Results

Our findings indicate a consistent upward trajectory in both publications and citations. Geographically, China holds the forefront in terms of publication volume, followed closely by the United States, India, and Japan. However, in citation quantity, the United States takes the lead, with China, India, and Italy trailing. Institutional contributions are led by the University of Pennsylvania in publication volume, while Harvard University ranks first in citation frequency. Notably, the Journal of Ethnopharmacology emerged as the most prolific journal and achieved a high citation ranking. The current research focal points encompass cell maturation, regenerative medicine, cellular replacement, and gene expression analysis.

Conclusion

This study offers an exhaustive bibliometric perspective on the global research trends concerning diabetic islet regeneration over the last decade. It highlights that areas such as beta-cell proliferation, regeneration, and replacement continue to be pivotal in the research landscape for diabetes management.
Appendix
Available only for authorised users
Literature
1.
go back to reference Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia. 2004;47(3):581–9.CrossRefPubMed Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia. 2004;47(3):581–9.CrossRefPubMed
2.
go back to reference Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–10.CrossRefPubMed Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–10.CrossRefPubMed
4.
go back to reference Thorel F, Népote V, Avril I, Kohno K, Desgraz R, Chera S, et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature. 2010;464(7292):1149–54.CrossRefPubMedPubMedCentral Thorel F, Népote V, Avril I, Kohno K, Desgraz R, Chera S, et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature. 2010;464(7292):1149–54.CrossRefPubMedPubMedCentral
5.
go back to reference Pagliuca FW, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, et al. Generation of functional human pancreatic β cells in vitro. Cell. 2014;159(2):428–39.CrossRefPubMedPubMedCentral Pagliuca FW, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, et al. Generation of functional human pancreatic β cells in vitro. Cell. 2014;159(2):428–39.CrossRefPubMedPubMedCentral
6.
go back to reference Ben-Othman N, Vieira A, Courtney M, Record F, Gjernes E, Avolio F, et al. Long-term GABA administration induces alpha cell-mediated beta-like cell neogenesis. Cell. 2017;168(1–2):73–85.e11. Ben-Othman N, Vieira A, Courtney M, Record F, Gjernes E, Avolio F, et al. Long-term GABA administration induces alpha cell-mediated beta-like cell neogenesis. Cell. 2017;168(1–2):73–85.e11.
7.
go back to reference Kerper N, Ashe S, Hebrok M. Pancreatic β-cell development and regeneration. Cold Spring Harb Perspect Biol. 2022;14(5):a040741. Kerper N, Ashe S, Hebrok M. Pancreatic β-cell development and regeneration. Cold Spring Harb Perspect Biol. 2022;14(5):a040741.
8.
go back to reference March CA, Libman IM, Becker DJ, Levitsky LL. From antiquity to modern times: a history of diabetes mellitus and its treatments. Horm Res Paediatr. 2022;95(6):593–607.CrossRefPubMed March CA, Libman IM, Becker DJ, Levitsky LL. From antiquity to modern times: a history of diabetes mellitus and its treatments. Horm Res Paediatr. 2022;95(6):593–607.CrossRefPubMed
9.
go back to reference Pylaev TE, Smyshlyaeva IV, Popyhova EB. Regeneration of β-cells of the islet apparatus of the pancreas. Literature review. Diabetes Mellitus. 2022;25(4):395–404.CrossRef Pylaev TE, Smyshlyaeva IV, Popyhova EB. Regeneration of β-cells of the islet apparatus of the pancreas. Literature review. Diabetes Mellitus. 2022;25(4):395–404.CrossRef
10.
go back to reference Mitsiou EK, Athyros VG, Karagiannis A, Mikhailidis DI. Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? Open Cardiovasc Med J. 2012;6:28–32.CrossRefPubMedPubMedCentral Mitsiou EK, Athyros VG, Karagiannis A, Mikhailidis DI. Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? Open Cardiovasc Med J. 2012;6:28–32.CrossRefPubMedPubMedCentral
11.
12.
go back to reference Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011;5(1):94–100.CrossRefPubMed Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011;5(1):94–100.CrossRefPubMed
13.
14.
go back to reference Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia. 2000;43(9):1165–9.CrossRefPubMed Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia. 2000;43(9):1165–9.CrossRefPubMed
15.
go back to reference Jiao YK, Wang XQ, Jiang X, Kong FS, Wang SM, Yan CY. Antidiabetic effects of <i>Morus alba</i> fruit polysaccharides on high-fat diet- and streptozotocin-induced type 2 diabetes in rats. J Ethnopharmacol. 2017;199:119–27.CrossRefPubMed Jiao YK, Wang XQ, Jiang X, Kong FS, Wang SM, Yan CY. Antidiabetic effects of <i>Morus alba</i> fruit polysaccharides on high-fat diet- and streptozotocin-induced type 2 diabetes in rats. J Ethnopharmacol. 2017;199:119–27.CrossRefPubMed
16.
go back to reference Cobo-Vuilleumier N, Gauthier BR. Time for a paradigm shift in treating type 1 diabetes mellitus: coupling inflammation to islet regeneration. Metab-Clin Exp. 2020;104:154137. Cobo-Vuilleumier N, Gauthier BR. Time for a paradigm shift in treating type 1 diabetes mellitus: coupling inflammation to islet regeneration. Metab-Clin Exp. 2020;104:154137.
17.
go back to reference Xu J, Lu Y, Ding F, Zhan X, Zhu M, Wang Z. Reversal of diabetes in mice by intrahepatic injection of bone-derived GFP-murine mesenchymal stem cells infected with the recombinant retrovirus-carrying human insulin gene. World J Surg. 2007;31(9):1872–82.CrossRefPubMed Xu J, Lu Y, Ding F, Zhan X, Zhu M, Wang Z. Reversal of diabetes in mice by intrahepatic injection of bone-derived GFP-murine mesenchymal stem cells infected with the recombinant retrovirus-carrying human insulin gene. World J Surg. 2007;31(9):1872–82.CrossRefPubMed
18.
go back to reference Ianus A, Holz GG, Theise ND, Hussain MA. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest. 2003;111(6):843–50.CrossRefPubMedPubMedCentral Ianus A, Holz GG, Theise ND, Hussain MA. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest. 2003;111(6):843–50.CrossRefPubMedPubMedCentral
19.
go back to reference Zhang Y, Shen W, Hua J, Lei A, Lv C, Wang H, et al. Pancreatic islet-like clusters from bone marrow mesenchymal stem cells of human first-trimester abortus can cure streptozocin-induced mouse diabetes. Rejuvenation Res. 2010;13(6):695–706.CrossRefPubMed Zhang Y, Shen W, Hua J, Lei A, Lv C, Wang H, et al. Pancreatic islet-like clusters from bone marrow mesenchymal stem cells of human first-trimester abortus can cure streptozocin-induced mouse diabetes. Rejuvenation Res. 2010;13(6):695–706.CrossRefPubMed
20.
go back to reference El-Haroun H, Salama RM. Comparative study on the therapeutic effects of bone marrow mesenchymal stem cells versus platelet rich plasma on the pancreas of adult male albino rats with streptozotocin-induced type 1 diabetes mellitus. Folia Morphol. 2022;81(1):65–81.CrossRef El-Haroun H, Salama RM. Comparative study on the therapeutic effects of bone marrow mesenchymal stem cells versus platelet rich plasma on the pancreas of adult male albino rats with streptozotocin-induced type 1 diabetes mellitus. Folia Morphol. 2022;81(1):65–81.CrossRef
21.
go back to reference Stewart AF, Hussain MA, García-Ocaña A, Vasavada RC, Bhushan A, Bernal-Mizrachi E, et al. Human β-cell proliferation and intracellular signaling: part 3. Diabetes. 2015;64(6):1872–85.CrossRefPubMedPubMedCentral Stewart AF, Hussain MA, García-Ocaña A, Vasavada RC, Bhushan A, Bernal-Mizrachi E, et al. Human β-cell proliferation and intracellular signaling: part 3. Diabetes. 2015;64(6):1872–85.CrossRefPubMedPubMedCentral
22.
go back to reference Meyerrose T, Olson S, Pontow S, Kalomoiris S, Jung Y, Annett G, et al. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev. 2010;62(12):1167–74.CrossRefPubMed Meyerrose T, Olson S, Pontow S, Kalomoiris S, Jung Y, Annett G, et al. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev. 2010;62(12):1167–74.CrossRefPubMed
23.
go back to reference Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36–45.CrossRefPubMed Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36–45.CrossRefPubMed
24.
go back to reference Zhou ZJ, Zhu XD, Huang HJ, Xu ZR, Jiang JH, Chen BC, et al. Recent progress of research regarding the applications of stem cells for treating diabetes mellitus. Stem Cells Dev. 2022;31(5–6):102–10.CrossRefPubMed Zhou ZJ, Zhu XD, Huang HJ, Xu ZR, Jiang JH, Chen BC, et al. Recent progress of research regarding the applications of stem cells for treating diabetes mellitus. Stem Cells Dev. 2022;31(5–6):102–10.CrossRefPubMed
25.
go back to reference Yanowski E, Yacovzada NS, David E, Giladi A, Jaitin D, Farack L, et al. Physically interacting beta-delta pairs in the regenerating pancreas revealed by single-cell sequencing. Mol Metab. 2022;60:101467. Yanowski E, Yacovzada NS, David E, Giladi A, Jaitin D, Farack L, et al. Physically interacting beta-delta pairs in the regenerating pancreas revealed by single-cell sequencing. Mol Metab. 2022;60:101467.
Metadata
Title
Global research trends on diabetic islet regeneration (2012–2022): a ten-year bibliometric study
Authors
Yulin Sun
Lingling Jia
Ying Wang
Rong Guo
Tingting Xi
Hua Jiang
Jiachao Xiong
Publication date
06-05-2024
Publisher
Springer India
Keyword
Diabetes
Published in
International Journal of Diabetes in Developing Countries
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-024-01341-5
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine